Skip to main content
SAMIL PHARMACEUTICAL CO.,LTD logo

SAMIL PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000520 ISIN · KR7000520007 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2021-05-17 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 000520

About SAMIL PHARMACEUTICAL CO.,LTD

https://www.samil-pharm.com/main/EN

Samil Pharmaceutical Co., Ltd. is a company engaged in the research, development, and manufacturing of pharmaceutical products. The company specializes in ophthalmology and also produces a diverse portfolio of drugs for other therapeutic areas, including the central nervous system (CNS), hepatic conditions, and gastrointestinal disorders. Its product range encompasses prescription medicines as well as over-the-counter remedies for common ailments like fever and colds. In addition to developing its own products, Samil Pharmaceutical offers Contract Development and Manufacturing Organization (CDMO) services to global partners. The company emphasizes research and development and collaborates with other leading pharmaceutical firms.

Recent filings

Filing Released Lang Actions
분기보고서 (2021.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Samil Pharmaceutical Co., Ltd. for the first quarter of 2021 (January 1, 2021, to March 31, 2021). It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2021
2021-05-17 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. This document details the shareholding changes of a company executive (Heo Seung-beom of Samil Pharm). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2021-05-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service in South Korea. It details the share acquisition (장내매수) by an executive (Heo Seung-bum) of Samil Pharmaceutical. This type of filing is a standard disclosure for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2021-05-07 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Samil Pharmaceutical. It details specific changes in share ownership by major shareholders and executives, including transaction dates and quantities. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks changes in significant ownership levels.
2021-05-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details the shareholding changes of a specific individual (Huh Kang) in Samil Pharmaceutical. This type of filing is a standard regulatory disclosure for insider holdings and transactions, which falls under the 'Director's Dealing' category in the provided schema.
2021-05-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure by company insiders (directors, executives, or major shareholders) regarding their shareholdings and changes therein. In the context of the provided categories, this falls under 'Director's Dealing' (DIRS), as it reports personal share ownership and changes (in this case, due to a stock split) by a company executive (CEO/Vice Chairman Heo Seung-bum).
2021-05-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.